[go: up one dir, main page]

AR077425A1 - Derivados de urea de tetrahidroquinoxalina, su preparacion y su uso en el tratamiento de enfermedades mediadas por la modulacion de la 11betahsd1 - Google Patents

Derivados de urea de tetrahidroquinoxalina, su preparacion y su uso en el tratamiento de enfermedades mediadas por la modulacion de la 11betahsd1

Info

Publication number
AR077425A1
AR077425A1 ARP100102695A ARP100102695A AR077425A1 AR 077425 A1 AR077425 A1 AR 077425A1 AR P100102695 A ARP100102695 A AR P100102695A AR P100102695 A ARP100102695 A AR P100102695A AR 077425 A1 AR077425 A1 AR 077425A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
nr6r7
alkoxy
halogenoalkyl
Prior art date
Application number
ARP100102695A
Other languages
English (en)
Inventor
Olivier Crespin
Eric Nicolai
Olivier Venier
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR077425A1 publication Critical patent/AR077425A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos que responden a la formula (1), en la que A representa un enlace, un átomo de oxígeno o un grupo -O-CH2-; Ar1 representa un grupo fenilo o heteroarilo; Ar2 representa un grupo fenilo, heteroarilo o heterocicloalquilo; R1a,b,c y R2a,b,c representan un átomo de hidrogeno o de halogeno o un grupo alquilo, cicloalquilo, .alquil-cicloalquilo sustituido opcionalmente con uno o varios átomos de halogeno, -OR5 (hidroxi o alcoxi), hidroxi-alquilo, alcoxi-alquilo, alcoxi-alcoxi, halogenoalquilo, -O-halogenoalquilo, oxo, -CO-alquilo, -CO-alquilo-NR6R7, -CO-halogenoalquilo, -COOR5, alquil-COOR5, -O-alquil-COOR5, -SO2-alquilo, -SO2-cicloalquilo, -SO2-alquil-cicloalquilo, -SO2-alquilo-OR5, -SO2-alquil-COOR5, -SO2-alquil-NR6R7 -SO2-halogenoalquilo, alquil-SO2-alquilo, -SO2-NR6R7, -SO2-alquil-O-alquil-OR5, -CONR6R7, -alquil-CONR6R7 o -O-alquil-NR6R7, o aun más R1a, R1b, R1c, están unidos respectivamente a R2a R2b, R2c y al átomo de carbono que les soporta y representan -O-alquil-O-; R3 representa un átomo de hidrogeno o un grupo alquilo; R4 representa un grupo -CONR6R7; hidroxi-alquilo sustituido con un grupo halogenoalquilo; -alquil-NH-SO2-alquilo; -NH-SO2-alquilo; -O-SO2-NR6R7; -alquilo-CO-NR6R7; -O-alquil-CO-NR6R7; -alquil-NR6R7; -O-CO-NR6R7; -alquil-heteroarilo; heteroarilo opcionalmente sustituido con un grupo alquilo; alcoxi-imino; -CO-NH-NH-CO-alquilo; con la condicion de que R4 esté en posicion cis cuando representa el grupo -CONR6R7 y que R6 y R7 representan cada uno hidrogeno, un grupo -alquilo o -alquil-fenilo; R5 representa hidrogeno, un grupo alquilo o un grupo -alquil-fenilo; R6 y R7, idénticos o diferentes, representan cada uno un átomo de hidrogeno, un grupo alquilo, alcoxi o un grupo -alquil-fenilo, y R5 representa un átomo de hidrogeno, un grupo -SO2- alquilo o un grupo de la formula -B-Het, en la que B puede estar ausente o representar un enlace, un átomo de oxígeno o un grupo -CO- o -SO2-(CH2)n con n igual a 0, 1 o 2 y en la que Het representa un heteroarilo o un heterocicloalquilo opcionalmente sustituido con los grupos alquilo, -SO2-alquilo y -COOR5. Procedimiento de preparacion y aplicacion en terapéutica, de enfermedades tales como la diabetes y la obesidad.
ARP100102695A 2009-07-27 2010-07-26 Derivados de urea de tetrahidroquinoxalina, su preparacion y su uso en el tratamiento de enfermedades mediadas por la modulacion de la 11betahsd1 AR077425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0903685A FR2948369B1 (fr) 2009-07-27 2009-07-27 Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR077425A1 true AR077425A1 (es) 2011-08-24

Family

ID=41508207

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102695A AR077425A1 (es) 2009-07-27 2010-07-26 Derivados de urea de tetrahidroquinoxalina, su preparacion y su uso en el tratamiento de enfermedades mediadas por la modulacion de la 11betahsd1

Country Status (5)

Country Link
US (1) US8536173B2 (es)
EP (1) EP2459548B1 (es)
AR (1) AR077425A1 (es)
FR (1) FR2948369B1 (es)
WO (1) WO2011012800A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
EP2518051A4 (en) * 2009-12-22 2013-10-16 Shionogi & Co ADAMANTANAMINE DERIVATIVE
WO2012020724A1 (ja) 2010-08-09 2012-02-16 塩野義製薬株式会社 アミノアダマンタンカルバメート誘導体の製造方法
BR112013022671A2 (pt) * 2011-03-08 2016-07-19 Basf Se processo para a preparação de aminas primárias, e, uso de um catalisador complexo
CN103275021B (zh) * 2013-05-24 2015-05-20 东北农业大学 N-二氯乙酰基-6,7-二氯-1,2,3,4-四氢喹喔啉及其制备方法
WO2019119040A1 (en) 2017-12-22 2019-06-27 Ccl Secure Pty Ltd Manufacturing a two-sided product with an integrated device including microscale structures

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960776A (en) 1987-01-28 1990-10-02 A. H. Robins Company, Inc. 4-aryl-N-(alkylaminoalkyl, heterocyclicamino and heterocyclicamino)alkyl)-1-piperazinecarboxamides
US20050209278A1 (en) 2002-04-25 2005-09-22 Mcdonald Joseph J Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
US7238724B2 (en) 2002-09-19 2007-07-03 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20050245745A1 (en) 2004-04-29 2005-11-03 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
PE20080344A1 (es) * 2006-06-27 2008-06-09 Sanofi Aventis Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1
PE20080212A1 (es) * 2006-06-27 2008-04-25 Sanofi Aventis Derivados de ureas de piperidina o pirrolidina como moduladores de la 11b-hidroxiesteroide deshidrogenasa tipo 1 (11bhsd1)
TW200936136A (en) * 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application

Also Published As

Publication number Publication date
FR2948369A1 (fr) 2011-01-28
WO2011012800A1 (fr) 2011-02-03
EP2459548A1 (fr) 2012-06-06
EP2459548B1 (fr) 2014-11-19
US8536173B2 (en) 2013-09-17
US20120165337A1 (en) 2012-06-28
FR2948369B1 (fr) 2013-04-12

Similar Documents

Publication Publication Date Title
CO6290672A2 (es) Derivados de urea de tetrahidroquinoxalina su preparacion aplicacion en terapeutica
AR077425A1 (es) Derivados de urea de tetrahidroquinoxalina, su preparacion y su uso en el tratamiento de enfermedades mediadas por la modulacion de la 11betahsd1
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
NI201200061A (es) Derivados de quinazolina-4(3h)-ona utilizados como inhibidores de la cinasa de pi3
ECSP088518A (es) Nucleósidos antivirales
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
AR071055A1 (es) Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas
ECSP14013264A (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
AR082519A1 (es) Fenilamidinas que tienen alta actividad fungicida, y su utilizacion
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ECSP11010750A (es) Derivados de indol macrocíclicos útiles como inhibidores del virus de la hepatitis c
CO6150150A2 (es) Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica
ECSP099216A (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR070485A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
UY34869A (es) Derivados de pirimidinonas, su preparación y su aplicación en terapéutica.
AR077499A1 (es) Derivados de urea de tetrahidroquinoxalina su preparacion y su aplicacion en terapia
ECSP078009A (es) Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica
AR075838A1 (es) Derivados de n-((6-aza-biciclo(3.2.1)oct-5-il)-aril-metil)-heterobenzamida, su preparacion y su aplicacion en terapeutica.
ECSP10010642A (es) Derivados de arilpirazinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso para el tratamiento de diabetes
AR054033A1 (es) Derivados de triazinas su preparacion y su aplicacion en terapeutica
AR081349A1 (es) Carboxamidas de pirazinilo como fungicidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure